{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:56:46Z","timestamp":1785859006022,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202309PJT-506389-PH2"],"award-info":[{"award-number":["202309PJT-506389-PH2"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adults with type 2 diabetes have increased risk of liver fibrosis, leading guidelines to recommend screening with the Fibrosis-4 Index (FIB-4). We assessed if modifications to Ontario Health Insurance Plan coverage of aspartate aminotransferase (AST) tests in 2013 were associated with changes in liver fibrosis assessment rates among adults with diabetes. This population-based cohort study included adults with diabetes and no history of liver disease in Ontario, Canada, from 2010 to 2022. Policy periods were constructed based on AST reimbursement practices. The primary outcome was the receipt of all laboratory tests needed to calculate FIB-4 (AST, alanine aminotransferase, and platelet count). Modified Poisson regression estimated the adjusted risk ratios (aRRs) for predictors of receiving liver fibrosis assessment. Interrupted time series analysis employed autoregressive integrated moving average models to assess both immediate and sustained policy effects. This study included 1,680,451 individuals; 47% were female; median age was 64\u00a0years [IQR, 55\u201373\u00a0years]. The annual proportion without any testing ranged from 39 to 47%. The risk of receiving all required tests for FIB-4 declined significantly: 12.7% (aRR 0.873, 0.869\u20130.877) during implementation, 33.9% (aRR 0.661, 0.657\u20130.664) post-intervention, and 63.1% (aRR 0.369, 0.366\u20130.371) COVID-19. Interrupted time-series analysis showed a significant immediate decline in monthly testing of FIB-4 components (\u2212\u20090.38; 95% CI\u2009\u2212\u20090.59 to\u2009\u2212\u20090.18), followed by a continued monthly decrease (\u2212\u20090.03; 95% CI\u2009\u2212\u20090.07 to 0.01). Restricting AST reimbursement was associated with a decline in liver fibrosis assessments for people with diabetes despite increasing consensus in favor of preventative screening.<\/jats:p>","DOI":"10.1038\/s41598-026-48600-5","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:04:40Z","timestamp":1777431880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Jessica","family":"Burnside","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Djerboua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Flemming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Betel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Nahwegahbow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb R.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica E. M.","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"4","key":"48600_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 77(4), 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"48600_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","volume":"122","author":"V Lekakis","year":"2024","unstructured":"Lekakis, V. & Papatheodoridis, G. V. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur. J. Intern. Med. 122, 3\u201310 (2024).","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"48600_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13(4), 643\u201354.e9 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"48600_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6(11), 903\u2013913 (2021).","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"48600_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2337\/dsi23-0014","volume":"37","author":"K Cusi","year":"2024","unstructured":"Cusi, K., Budd, J., Johnson, E. & Shubrook, J. Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: What clinicians need to know. Diabetes Spectr. 37(1), 29\u201338 (2024).","journal-title":"Diabetes Spectr."},{"issue":"6","key":"48600_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","volume":"19","author":"JP Arab","year":"2020","unstructured":"Arab, J. P. et al. Latin American association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann. Hepatol. 19(6), 674\u2013690 (2020).","journal-title":"Ann. Hepatol."},{"issue":"3","key":"48600_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke, F. et al. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81(3), 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"issue":"5","key":"48600_CR8","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5), 1797\u20131835 (2023).","journal-title":"Hepatology"},{"issue":"7","key":"48600_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi, K. et al. Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American diabetes association. Diabetes Care 48(7), 1057\u20131082 (2025).","journal-title":"Diabetes Care"},{"issue":"4","key":"48600_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jcjd.2025.04.003","volume":"49","author":"J Kim","year":"2025","unstructured":"Kim, J., Bajaj, H. S., Ramji, A., Bemeur, C. & Sebastiani, G. Diabetes and metabolic dysfunction-associated steatotic liver disease in adults: A clinical practice guideline. Can. J. Diabetes 49(4), 222\u2013236 (2025).","journal-title":"Can. J. Diabetes"},{"issue":"11","key":"48600_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078962","volume":"8","author":"M Zhi","year":"2013","unstructured":"Zhi, M., Ding, E. L., Theisen-Toupal, J., Whelan, J. & Arnaout, R. The landscape of inappropriate laboratory testing: A 15-year meta-analysis. PLoS ONE 8(11), e78962 (2013).","journal-title":"PLoS ONE"},{"key":"48600_CR12","unstructured":"Ontario Health Technology Advisory Committee. Appropriateness phase 1 OHTAC recommendations: annual health exams, aspartate aminotransferase testing, chloride testing, creatine kinase testing, ferritin testing, folate testing, and vitamin B12 testing. . 2013. https:\/\/www.hqontario.ca\/Portals\/0\/Documents\/evidence\/reports\/recommendation-appropriateness-phase-1-130722-en.pdf."},{"key":"48600_CR13","unstructured":"McCurdy B. Aspartate aminotransferase testing in community-based laboratories: an expert consultation. Toronto, ON: Health Quality Ontario; 2013 June. p. 11."},{"issue":"2","key":"48600_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.healthpol.2020.10.007","volume":"125","author":"N Chami","year":"2021","unstructured":"Chami, N., Li, Y., Weir, S., Wright, J. G. & Kantarevic, J. Effect of strict and soft policy interventions on laboratory diagnostic testing in Ontario, Canada: A Bayesian structural time series analysis. Health Policy 125(2), 254\u2013260 (2021).","journal-title":"Health Policy"},{"key":"48600_CR15","unstructured":"Schedule of benefits for laboratory services. Ministry of Health; 2023. p. 7."},{"key":"48600_CR16","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jcjd.2017.10.005","volume":"42","author":"M Clement","year":"2018","unstructured":"Clement, M. et al. Organization of diabetes care. Can. J. Diabetes 42, S27\u2013S35 (2018).","journal-title":"Can. J. Diabetes"},{"key":"48600_CR17","unstructured":"Office of the Auditor General of Ontario. 2017 annual report volume 1: chapter 3: reports on value-for-money audits. 3.07 Laboratory services in the health sector. https:\/\/www.auditor.on.ca\/en\/content\/annualreports\/arreports\/en17\/v1_307en17.pdf."},{"issue":"2","key":"48600_CR18","first-page":"1135","volume":"4","author":"MJ Schull","year":"2020","unstructured":"Schull, M. J. et al. ICES: Data, discovery, better health. Int J Popul Data Sci 4(2), 1135 (2020).","journal-title":"Int J Popul Data Sci"},{"issue":"3","key":"48600_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2337\/diacare.25.3.512","volume":"25","author":"JE Hux","year":"2002","unstructured":"Hux, J. E., Ivis, F., Flintoft, V. & Bica, A. Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25(3), 512\u2013516 (2002).","journal-title":"Diabetes Care"},{"issue":"1","key":"48600_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","volume":"18","author":"LL Lipscombe","year":"2018","unstructured":"Lipscombe, L. L. et al. Identifying diabetes cases from administrative data: A population-based validation study. BMC Health Serv. Res. 18(1), 316 (2018).","journal-title":"BMC Health Serv. Res."},{"key":"48600_CR21","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jcjd.2017.10.004","volume":"42","author":"J-M Ekoe","year":"2018","unstructured":"Ekoe, J.-M., Goldenberg, R. & Katz, P. Screening for diabetes in adults. Can. J. Diabetes 42, S16\u2013S19 (2018).","journal-title":"Can. J. Diabetes"},{"key":"48600_CR22","unstructured":"Dynacare. Partner Update: restrictions to OHIP coverage of AST and folate. 2017. https:\/\/www.dynacare.ca\/DYN\/media\/DYN\/eng\/Notices-%20Locations\/2017\/AST_folate_Final_EN_03MAR2017_website.pdf."},{"issue":"9","key":"48600_CR23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","volume":"59","author":"S McPherson","year":"2010","unstructured":"McPherson, S., Stewart, S. F., Henderson, E., Burt, A. D. & Day, C. P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59(9), 1265\u20131269 (2010).","journal-title":"Gut"},{"key":"48600_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1457598","volume":"15","author":"Y Xuan","year":"2024","unstructured":"Xuan, Y. et al. Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: Insights from a cross-sectional analysis in the United States. Front Endocrinol 15, 1457598 (2024).","journal-title":"Front Endocrinol"},{"issue":"5","key":"48600_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.amjms.2024.01.022","volume":"367","author":"S Condon","year":"2024","unstructured":"Condon, S., Hu, H., Kong, M., Cave, M. C. & McClain, C. J. ALT poorly predicts nonalcoholic fatty liver disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult national health and nutrition examination survey 2017\u20132018. Am. J. Med. Sci. 367(5), 310\u2013322 (2024).","journal-title":"Am. J. Med. Sci."},{"issue":"4","key":"48600_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3138\/canlivj-2025-0026","volume":"8","author":"DA Dinh","year":"2025","unstructured":"Dinh, D. A. et al. Barriers and facilitators to liver fibrosis screening: Perspectives and practices of Canadian primary care physicians. Can. Liver J. 8(4), 554\u2013566 (2025).","journal-title":"Can. Liver J."},{"issue":"4","key":"48600_CR27","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4), 1560\u20131599 (2018).","journal-title":"Hepatology"},{"issue":"1","key":"48600_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-021-01235-8","volume":"21","author":"AL Schaffer","year":"2021","unstructured":"Schaffer, A. L., Dobbins, T. A. & Pearson, S.-A. Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: A guide for evaluating large-scale health interventions. BMC. Med. Res. Methodol. 21(1), 58 (2021).","journal-title":"BMC. Med. Res. Methodol."},{"issue":"24","key":"48600_CR29","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.3390\/jcm10245755","volume":"10","author":"LJ Dobbie","year":"2021","unstructured":"Dobbie, L. J. et al. Low screening rates despite a high prevalence of significant liver fibrosis in people with diabetes from primary and secondary care. J. Clin. Med. 10(24), 5755 (2021).","journal-title":"J. Clin. Med."},{"key":"48600_CR30","doi-asserted-by":"publisher","first-page":"112193","DOI":"10.1016\/j.diabres.2025.112193","volume":"224","author":"EK Fenwick","year":"2025","unstructured":"Fenwick, E. K. et al. Non-adherence to diabetes microvascular complications follow-up screening in the primary care population: Predictors, associated barriers, and facilitators. Diabetes Res Clin Pract 224, 112193 (2025).","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"48600_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.18808","volume":"7","author":"D Edmonston","year":"2024","unstructured":"Edmonston, D. et al. Concordance With screening and treatment guidelines for chronic kidney disease in type 2 diabetes. JAMA Netw Open 7(6), e2418808 (2024).","journal-title":"JAMA Netw Open"},{"issue":"3","key":"48600_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09286586.2018.1424344","volume":"25","author":"J An","year":"2018","unstructured":"An, J., Niu, F., Turpcu, A., Rajput, Y. & Cheetham, T. C. Adherence to the American diabetes association retinal screening guidelines for population with diabetes in the United States. Ophthalmic. Epidemiol. 25(3), 257\u2013265 (2018).","journal-title":"Ophthalmic. Epidemiol."},{"issue":"8","key":"48600_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003320","volume":"3","author":"Y Wang","year":"2013","unstructured":"Wang, Y., Hunt, K., Nazareth, I., Freemantle, N. & Petersen, I. Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open 3(8), e003320 (2013).","journal-title":"BMJ Open"},{"issue":"6","key":"48600_CR34","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.pcd.2021.08.004","volume":"15","author":"D O\u2019Keeffe","year":"2021","unstructured":"O\u2019Keeffe, D., Riordan, F., Harkins, V., Kearney, P. & Mc, H. S. Predictors of attendance at diabetic retinopathy screening among people with type 2 diabetes: Secondary analysis of data from primary care. Prim. Care Diabetes 15(6), 1086\u20131094 (2021).","journal-title":"Prim. Care Diabetes"},{"issue":"9","key":"48600_CR35","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1007\/s11606-020-05747-9","volume":"35","author":"J Nichols","year":"2020","unstructured":"Nichols, J., Shah, B. R., Pequeno, P., Gall Casey, C. & Yu, C. H. Impact of a comprehensive guideline dissemination strategy on diabetes diagnostic test rates: an interrupted time series. J Gen Intern Med 35(9), 2662\u20132667 (2020).","journal-title":"J Gen Intern Med"},{"issue":"3","key":"48600_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.34172\/mejdd.2020.182","volume":"12","author":"S Kolahdoozan","year":"2020","unstructured":"Kolahdoozan, S. et al. Upper normal limits of serum alanine aminotransferase in healthy population: A systematic review. Middle East J. Dig. Dis. 12(3), 194\u2013205 (2020).","journal-title":"Middle East J. Dig. Dis."},{"issue":"6","key":"48600_CR37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/MEG.0b013e32835d72cf","volume":"25","author":"S McPherson","year":"2013","unstructured":"McPherson, S., Anstee, Q. M., Henderson, E., Day, C. P. & Burt, A. D. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. Eur. J. Gastroenterol. Hepatol. 25(6), 652\u2013658 (2013).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"48600_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101280","volume":"29","author":"J Lee","year":"2024","unstructured":"Lee, J. et al. Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT. Ann. Hepatol. 29(2), 101280 (2024).","journal-title":"Ann. Hepatol."},{"issue":"1","key":"48600_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062158","volume":"13","author":"T Wang","year":"2023","unstructured":"Wang, T., Tan, J. B., Liu, X. L. & Zhao, I. Barriers and enablers to implementing clinical practice guidelines in primary care: An overview of systematic reviews. BMJ Open 13(1), e062158 (2023).","journal-title":"BMJ Open"},{"issue":"1","key":"48600_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13012-022-01223-6","volume":"17","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. Trends in guideline implementation: an updated scoping review. Implement Sci 17(1), 50 (2022).","journal-title":"Implement Sci"},{"key":"48600_CR41","unstructured":"Kingston Health Sciences Centre. Primary care management Pathwat non-alcoholic fatty liver disease. 2022. https:\/\/kingstonhsc.ca\/sites\/default\/files\/legacy\/files\/subsite-basic-page\/nafld_pathway_27april22.pdf."},{"key":"48600_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2020-001219","author":"Z Mohammed-Ali","year":"2021","unstructured":"Mohammed-Ali, Z. et al. Implementing effective test utilization via team-based evaluation and revision of a family medicine laboratory test requisition. BMJ Open Qual. https:\/\/doi.org\/10.1136\/bmjoq-2020-001219 (2021).","journal-title":"BMJ Open Qual."},{"issue":"10","key":"48600_CR43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/bmjqs-2018-008991","volume":"28","author":"R Strauss","year":"2019","unstructured":"Strauss, R. et al. Major reductions in unnecessary aspartate aminotransferase and blood urea nitrogen tests with a quality improvement initiative. BMJ Qual. Saf. 28(10), 809 (2019).","journal-title":"BMJ Qual. Saf."},{"key":"48600_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2025.110951","volume":"138","author":"DR Beriault","year":"2025","unstructured":"Beriault, D. R. et al. Choosing Wisely Canada recommendations for clinical biochemistry: Test ordering for sustainable and high-quality patient care. Clin. Biochem. 138, 110951 (2025).","journal-title":"Clin. Biochem."},{"key":"48600_CR45","unstructured":"Diabetes in Ontario: backgrounder. Toronto: Diabetes Canada. 2024. https:\/\/www.diabetes.ca\/getmedia\/b4f2add1-c56b-48e5-93cd-beb9feebb667\/2024-Backgrounder-Ontario.pdf."}],"updated-by":[{"DOI":"10.1038\/s41598-026-64893-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48600-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:37:27Z","timestamp":1785847047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48600-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48600"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48600-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-64893-y","URL":"https:\/\/doi.org\/10.1038\/s41598-026-64893-y","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.S.:\u00a0speaker for Merck, Gilead,\u00a0Abbvie, Novo Nordisk, Eli Lilly, Pfizer, and served as an advisory board member for Gilead, GlaxoSmithKline, Merck, Novo Nordisk. H.S.B.: Trial fees from Abbott, Amgen, Anji Pharmaceuticals, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Novo Nordisk, Pfizer, Vertex. K.P.: Consultant and advisory board: Novo Nordisk, Merck, Boehringer-Ingelheim. Data Safety Committee: Gilead Sciences, Galectin.\u00a0M.Betel: speaker for Medscape Education, Novo Nordisk, Boehringer and served as an advisory board member for PPD, Worldwide Clinical Studies, Regeneron, WebMD, Sonic Incytes and Madrigal. Fatty Liver Alliance has received unrestricted funding from Madrigal Pharmaceuticals, Novo Nordisk, Regeneron, Perspectum, Aegle Medical, Medscape,\u00a0Echosens, PPD\/Evidera, Siemens-Healthineers, Mind-Ray. S.S. has served as an advisory board member and consultant for Novo Nordisk. No conflicts were reported by the following authors: J.B., M.D., J.A.F., W.W.L.W., Z.L., M.B., A.N., Z.R.G., and E.E.M.M.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"19842"}}